NephroPlus Q3 FY26: Revenue up 31.7%, PAT jumps 71.3% YoY
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.3 pts more than Nifty Microcap 250 and 8.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NephroPlus posted strong Q3 FY26 results. Revenue rose 31.7 percent YoY to Rs 259.7 cr; 9M revenue up 36.6 percent to Rs 733.2 cr. Adjusted EBITDA grew 43 percent to Rs 63.1 cr with margin expanding 190 bps to 24.3 percent. Adjusted PAT surged 71.3 percent to Rs 34.4 cr. Growth driven by 17.7 percent rise in treatment volumes and a shift to higher-priced international markets, whose revenue share rose to 41.1 percent from 29.5 percent. Annualized RoCE improved 600 bps to 24.7 percent.
Strong beat across revenue, margins, and profitability. International mix is improving returns. Positive read for the stock.